Cytoagents is a clinical stage therapeutics company developing CTO1681, an oral small molecule immune modulator to prevent and treat Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)  by tamping down excessive inflammation by downregulating cytokine production and restoring normal immune function.  By effectively preventing CRS in CAR T-Cell Therapy and then expanding into other immunotherapies, CytoAgents will remove one of the major obstacles standing in the way of widescale adoption of these breakthrough therapies. CTO1681 is currently conducting a Phase 1b/2a Clinical Tria in Lymphoma Patients Receiving CART at Risk for CRS and ICANS.

Website: www.cytoagents.com